Recent advances in the development of novel glucocorticoid receptor modulators

Bibliography

• Morand EF. Effects of glucocorticoids on inflammation and arthritis. Curr Opin Rheumatol 2007;19:302-7
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Glucocorticosteroids. In: Kay AB, editor, Allergy and allergic diseases. (Volume 1). Wiley-Blackwell, Oxford, UK; 2008. p. 715-31
   Google Scholar
• Schmidt S, Rainer J, Ploner C, Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004;11:S45-S55
   PubMed Web of Science ®Google Scholar
• Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43
   PubMed Web of Science ®Google Scholar
• Caplan L, Saag KG. Glucocorticoids and the risk of osteoporosis. Expert Opin Drug Safety 2009;8:33-47
   PubMed Web of Science ®Google Scholar
• Marques AH, Silverman MN, Sternberg EM. Glucocorticoid dysregulations and their clinical correlates: from receptors to therapeutics. Ann NY Acad Sci 2009;1179:1-18
   Google Scholar
• Cole TJ. Glucocorticoid action and the development of selective glucocorticoid receptor ligands. Biotechnol Ann Rev 2006;12:269-300
   PubMedGoogle Scholar
• Schacke H, Berger M, Hansson TG, Dissociated non-steroidal glucocorticoid receptor modulators: an update on new compounds. Expert Opin Ther Patents 2008;18:339-52
   Web of Science ®Google Scholar
• Mohler ML, He Y, Wu Z, Non-steroidal glucocorticoid receptor antagonists: the race to replace RU-486 for anti-glucocorticoid therapy. Expert Opin Ther Patents 2007;17:59-81
   PubMed Web of Science ®Google Scholar
• Hudson AR, Roach SL, Higuchi RI. Recent developments in the discovery of selective glucocorticoid receptor modulators (SGRMs). Curr Top Med Chem 2008;8:750-65
   Google Scholar
• Takahashi H, Razavi H, Thomson D. Recent progress in the discovery of novel glucocorticoid receptor modulators. Curr Top Med Chem 2008;8:521-30
   PubMed Web of Science ®Google Scholar
• Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008;4:525-33
   PubMedGoogle Scholar
• Lowenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2008;73:1025-9
   PubMed Web of Science ®Google Scholar
• McMaster A, Ray DW. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects. Exp Physiol 2007;92:299-309
   PubMed Web of Science ®Google Scholar
• Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 2007;275:43-61
   PubMed Web of Science ®Google Scholar
• Perissi V, Rosenfeld MG. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 2005;6:542-54
   PubMed Web of Science ®Google Scholar
• Ronacher K, Hadley K, Avenant C, Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction. Mol Cell Endocrinol 2009;299:219-31
   PubMed Web of Science ®Google Scholar
• Luo M, Simons SS. Modulation of glucocorticoid receptor induction properties by cofactors in peripheral blood mononuclear cells. Hum Immunol 2009;70:785-9
   PubMedGoogle Scholar
• Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007;275:109-17
   PubMed Web of Science ®Google Scholar
• Heck S, Kullmann M, Gast A, A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J 1994;13:4087-95
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Kaestner KH, Tuckermann J, DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998;93:531-41
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Tuckermann J, Gottlicher M, Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001;20:7168-73
   PubMed Web of Science ®Google Scholar
• Schacke H, Schottelius A, Docke WD, Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004;101:227-32
   PubMed Web of Science ®Google Scholar
• Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;3:950-64
   PubMed Web of Science ®Google Scholar
• See, for example, on interspecies differences in glucocorticoid sensitivity: Necela BM, Cidlowski JA. A single amino acid change in the first zinc finger of the DNA binding domain of the glucocorticoid receptor regulates differential promoter selectivity. J Biol Chem 2004;279:39279-88 and references therein
   PubMedGoogle Scholar
• Labeur M, Arzt E, Stalla GK, Paez-Pereda M. New perspectives in the treatment of Cushing's syndrome. Curr Drug Targets Immune Endocr Metab Disord 2004;4:335-42
   PubMedGoogle Scholar
• Tomlinson JW, Stewart PM. Modulation of glucocorticoid action and the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007;21:607-19
   PubMed Web of Science ®Google Scholar
• Li QY, Zhang M, Hallis TM, Characterization of a novel non-steroidal glucocorticoid receptor antagonist. Biochem Biophys Res Commun 2010;391:1531-6
   Google Scholar
• Zinker B, Mika A, Nguyen P, Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance. Metab Clin Exp 2007;56:380-7
   Google Scholar
• Brazzini B, Pimpinelli N. New and established corticosteroids in dermatology. Clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002;3:47-58
   PubMedGoogle Scholar
• Bodor N, Buchwald P. Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of the soft corticosteroids. Curr Pharm Des 2006;12:3241-60
   PubMed Web of Science ®Google Scholar
• In discussion of the structural elements of generic coverage here and elsewhere brackets imply an optional characteristic. Thus, “(hetero)cycloalkyl” means a heterocycloalkyl or a cycloalkyl.
   Google Scholar
• Boehringer Ingelheim International GMBH. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof. WO2009149139; 2009
   Google Scholar
• Bayer Schering Pharma, AstraZeneca AB. 5-[(3,3,3-Trifluoro-2-hydroxy1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents. WO2009065503; 2009
   Google Scholar
• Schering AG. 5-Substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics. WO2006050998; 2006
   Google Scholar
• Schacke H, Zollner TM, Docke WD, Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 2009;158:1088-103
   PubMed Web of Science ®Google Scholar
• Available from: http://www.thomson-pharma.com, [Last accessed February 2010]
   Google Scholar
• Hoffmann–La Roche AG. 1,1,1-Trifluoro-2-hydroxy-3-phenylpropane derivatives. WO2009040288; 2009
   Google Scholar
• Kyowa Hakko Kirin. Nitrogenated compound. WO2009069736; 2009
   Google Scholar
• Fried JH, Mrozik H, Arth GE, 16-Methylated steroids. IV6, 16α-Dimethyl-Δ6-hydrocortisone and related compounds. J Am Chem Soc 1963;85:236-8
   Google Scholar
• Suino-Powell K, Xu Y, Zhang C, Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol. Mol Cell Biol 2008;28:1915-23
   PubMed Web of Science ®Google Scholar
• Madauss KP, Bledsoe RK, McLay I, The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist. Bioorg Med Chem Lett 2008;18:6097-9
   PubMed Web of Science ®Google Scholar
• Glaxo Group Ltd. Indazoles as glucocorticoid receptor ligands. WO2006108699; 2006
   Google Scholar
• Glaxo Group Ltd. Phenyl-pyrazole derivatives as non-steroidal glucocorticoid receptor ligands. WO2007000334; 2007
   Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2007144327; 2007
   Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2008043789; 2008
   Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2008000777; 2008
   Google Scholar
• Glaxo Group Ltd. Pyrazole derivatives as non-steroidal glucocorticoid receptor ligands. WO2008074814; 2008
   Google Scholar
• Biggadike K, Bledsoe RK, Coe DM, Design and x-ray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptor. Proc Natl Acad Sci USA 2009;106:18114-9
   PubMed Web of Science ®Google Scholar
• Glaxo Group Ltd. Novel compounds. WO2008043788; 2008
   Google Scholar
• Glaxo Group Ltd. Indazoles as glucocorticoid receptor ligands. WO2009050244; 2009
   Google Scholar
• Glaxo Group Ltd. Indazoles as glucocorticoid receptor ligands. WO2009050220; 2009
   Google Scholar
• Glaxo Group Ltd. Indazoles as glucocorticoid receptor ligands. WO2009050218; 2009
   Google Scholar
• Glaxo Group Ltd. Indazoles as glucocorticoid receptor ligands. WO2009050243; 2009
   Google Scholar
• Glaxo Group Ltd. Indazoles as glucocorticoid receptor ligands. WO2009050221; 2009
   Google Scholar
• Glaxo Group Ltd. N-(2{[1-Phenyl-1H-indazol-4-yl]amino}propyl)-sulfonamide derivatives as non-steroidal glucocorticoid receptor ligands for the treatment of inflammations. WO2009074590; 2009
   Google Scholar
• Glaxo Group Ltd. Pyrazolo[3,4-d]pyrimidine derivatives for the treatment of inflammation and/or allergic conditions. WO2008135578; 2008
   Google Scholar
• AstraZeneca AB, Bayer Schering Pharma AG. Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders. WO2008076048; 2008
   Google Scholar
• AstraZeneca AB, Bayer Schering Pharma AG. Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders. WO2008079073; 2008
   Google Scholar
• AstraZeneca AB, Bayer Schering Pharma AG. Phenyl or pyridinyl substituted indazole derivatives. WO2009142569; 2009
   Google Scholar
• AstraZeneca AB, Bayer Schering Pharma AG. Phenyl and benzodioxinyl substituted indazole derivatives. WO2009142571; 2009
   Google Scholar
• Boehringer Ingelheim International GMBH. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof. WO2008070507; 2008
   Google Scholar
• Bayer Schering Pharma AG, AstraZeneca AB. Indole and indazole derivatives as anti-inflammatory agents. WO2008055710; 2008
   Google Scholar
• Available from: http://register.epoline.org [Last accessed February 2010]
   Google Scholar
• Available from: http://portal.uspto.gov [Last accessed February 2010]
   Google Scholar
• Bayer Schering Pharma AG, AstraZeneca AB. Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents. WO2008098798; 2008
   Google Scholar
• Schering AG. 1-Amino-2-oxy-substituted tetrahydronaphthalene derivatives, methods for the production thereof, and their use as antiphlogistics. WO2005034939; 2005
   Google Scholar
• Bristol–Myers Squibb. Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. WO2008057856; 2008
   Google Scholar
• Bristol–Myers Squibb. Indane modulators of glucocorticoid receptor. AP-1 and/or NF-κB activity and use thereof. WO2007073503; 2007
   Google Scholar
• Bristol–Myers Squibb. Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. WO2008057862; 2008
   Google Scholar
• Bristol–Myers Squibb. Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. WO2008057859; 2008
   Google Scholar
• Bristol–Myers Squibb. Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. WO2008057857; 2008
   Google Scholar
• AstraZeneca AB. Steroidal [3,2-c]pyrazole compounds, with glucocorticoid activity. WO2009044200; 2009
   Google Scholar
• AstraZeneca AB. Steroid derivatives acting as glucocorticosteroid receptor agonists. WO2009082342; 2009
   Google Scholar
• Merck & Co. Hexahydrocyclopentyl[f]indazole sulfonamides and derivatives thereof as selective glucocorticoid receptor modulators. WO2009111214; 2009
   Google Scholar
• Merck & Co. 2-[1-Phenyl-5-hydroxy or methoxy-4alpha-methylhexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands. WO2008060391; 2008
   Google Scholar
• Merck & Co. 2-[1-Phenyl-5-hydroxy or methoxy-4alpha-methylhexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands. WO2008051532; 2008
   Google Scholar
• Merck & Co. Process for making glucocorticoid receptor ligands. WO2009054925; 2009
   Google Scholar
• Dainippon Sumitomo Pharma. Novel fused pyrrole derivative. JP2008247781; 2008
   Google Scholar
• Dainippon Sumitomo Pharma. WO2008120661; 2008
   Google Scholar
• Bristol–Myers Squibb. Nonsteroidal compounds useful as modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. WO2009058944; 2009
   Google Scholar
• Bristol–Myers Squibb. Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. US7625921; 2009
   Google Scholar
• Bristol–Myers Squibb. Heterocyclic modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. US7605264; 2009
   Google Scholar
• Bristol–Myers Squibb. Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. US7569689; 2009
   Google Scholar
• Yang BV, Vaccaro W, Doweyko AM, Discovery of novel dihydro-9, 10-ethano-anthracene carboxamides as glucocorticoid receptor modulators. Bioorg Med Chem Lett 2009;19:2139-43
   PubMed Web of Science ®Google Scholar
• Bristol–Myers Squibb. Fused heteroaryl modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. WO2009100171; 2009
   Google Scholar
• Bristol–Myers Squibb. Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof. WO2008021926; 2008
   Google Scholar
• Tanabe Seiyaku. Preparation of fused tetrahydroquinolines as glucocorticoid receptor modulators. JP2009046435; 2009
   Google Scholar
• Kyowa Hakko Kirin. Tetracyclic compound. WO2010001990; 2010
   Google Scholar
• Eli Lilly. Glucocorticoid receptor modulator and methods of use. WO2008008882; 2008
   Google Scholar
• Eli Lilly. (E)-N-{3-[1-(8-Fluoro-11H-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-phenyl}-methylsulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid. WO2009089312; 2009
   Google Scholar
• Pfizer Products, Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators. WO2008093236; 2008
   Google Scholar
• Pfizer Products, Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators. WO2008093227; 2008
   Google Scholar
• Morgan BP, Swick AG, Hargrove DM, Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem 2002;45:2417-24
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov, [Last accessed February 2010]
   Google Scholar
• Eli Lilly. Tricyclic steroid hormone nuclear receptor modulators. WO2005066153; 2005
   Google Scholar
• Eli Lilly. Tricyclic steroid hormone nuclear receptor modulators. WO2005066161; 2005
   Google Scholar
• Santen Pharmaceutical. Novel 1,3,3-trimethyl-7-phenyl-3,4-dihydro-1H-quinoxalin-2-one derivatives. WO2009035068; 2009
   Google Scholar
• Santen Pharmaceutical. Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity. WO2008146871; 2008
   Google Scholar
• Santen Pharmaceutical. Glucocorticoid receptor agonists consisting of 1,3,3-trimethyl-7-phenyl-3,4-dihydro-1H-quinoxalin-2-one derivatives. WO2009035067; 2009
   Google Scholar
• Santen Pharmaceutical. Novel 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents. WO2008059865; 2008
   Google Scholar
• Santen Pharmaceutical. Novel 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents. WO2008059866; 2008
   Google Scholar
• Santen Pharmaceutical. Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents. WO2008059867; 2008
   Google Scholar
• Santen Pharmaceutical. Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative having substituted oxy group. WO2009139361; 2009
   Google Scholar
• Santen Pharmaceutical. Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative. WO2008111632; 2008
   Google Scholar
• Santen Pharmaceutical. Condensed tetrahydroquinoline derivative and use thereof for medical purposes. WO2008087936; 2008
   Google Scholar
• Ligand Pharmaceuticals. Steroid hormone receptor modulator compounds and methods. WO2009103007; 2009
   Google Scholar
• Boehringer Ingelheim International GMBH. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof. WO2008124745; 2008
   Google Scholar
• Boehringer Ingelheim International GMBH. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof. WO2008124665; 2008
   Google Scholar
• Boehringer Ingelheim International GMBH. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof. WO2009015067; 2009
   Google Scholar
• AstraZeneca AB. Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (COPD) and asthma. WO2008103126; 2008
   Google Scholar
• Bristol–Myers Squibb. Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-Kappa B activity and use thereof. WO2009158380; 2009
   Google Scholar
• Pfizer Products Inc. Novel glucocorticoid receptor agonists. WO2009069032; 2009
   Google Scholar
• AstraZeneca AB. 16 Alpha, 17 alpha-acetal glucocorticosteroidal derivatives and their use. WO2009108118; 2009
   Google Scholar
• Tianjin Pharmaceuticals. Preparation of androstane glucocorticoid receptor agonist compounds with anti-inflammatory effects and application in treatment of inflammatory and allergic diseases. CN101372499; 2009
   Google Scholar
• Schering Corporation. C20-C21 substituted glucocorticoid receptor agonists. WO2009085879; 2009
   Google Scholar
• Schering Corporation. C-21 thioethers as glucocorticoid receptor agonists. WO2009085880; 2009
   Google Scholar
• AstraZeneca AB. Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity. WO2009154562; 2009
   Google Scholar
• AstraZeneca AB. A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist. WO2010008341; 2010
   Google Scholar
• AstraZeneca AB. Combination comprising 6-fluoro-N-((1S,4S)-4- (6-fluoro-2,4-dioxo-1-(4′-(piperazin-1-ylmethyl)biphenyl-3-yl)-1,2-dihydropyrido[2,3-d]pyrimidin-3(4H)-yl)cyclohexyl)imidazo[1,2-a]pyridine-2-carboxamide or a salt. WO2010004319; 2010
   Google Scholar
• AstraZeneca AB. Bayer Schering Pharma AG. Combination of (a) chemokine receptor 1 (CCR1) antagonist and (b) glucocorticoid receptor modulator. WO2009142588; 2009
   Google Scholar
• Glaxo Group Ltd. Pharmaceutical composition comprising a non-steroidal glucocorticoid receptor agonist in combination with a dual histamine antagonist. WO2009153296; 2009
   Google Scholar
• NV Organon. Use of glucocorticoid receptor antagonists for treatment of infectious conditions. WO2008017658; 2008
   Google Scholar
• Bausch & Lomb. Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof. US2008033008; 2008
   Google Scholar
• Speedel Experimenta AG. Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist. EP1886695; 2008
   Google Scholar